The US Meals and Drug Administration at present permitted a capsule model of the blockbuster anti-obesity drug Wegovy. Made by Novo Nordisk, the capsule is taken as soon as a day. The corporate’s authentic model of Wegovy is a weekly injection. Each medication comprise the identical energetic ingredient, semaglutide.
“This enables sufferers with weight problems who wish to shed weight to have a alternative between a as soon as weekly injection or a day by day pill,” says Martin Holst Lange, chief scientific officer at Novo Nordisk.
With the hovering recognition of injectable GLP-1 medication for weight reduction, Novo Nordisk and different pharmaceutical corporations have been racing to make effective pill versions that could possibly be preferable for some sufferers. These medication mimic a naturally occurring hormone within the physique that acts on the mind and intestine to advertise a sense of fullness.
In clinical trial results revealed within the New England Journal of Drugs, contributors who took the capsule achieved a mean weight lack of 13.6 % by 64 weeks. Almost 30 % of individuals misplaced 20 % or extra of their weight. The research additionally confirmed enhancements in heart problems threat and bodily exercise ranges much like the injectable model.
Whereas drugs can generally be a extra handy choice, sufferers might not all the time take them as prescribed, making them much less efficient. The medical trial investigators estimated that in a super situation the place contributors take the capsule each day as prescribed, weight reduction can be 16.6 %—which has similarities to outcomes seen with injectable Wegovy.
Novo Nordisk first gained approval for an oral semaglutide, bought beneath the model identify Rybelsus, in 2019 to deal with kind 2 diabetes. That drug has by no means been permitted for weight problems and isn’t as efficient for weight reduction as newer GLP-1 drugs. The Wegovy capsule is actually a higher-dose model of Rybselsus.
“The efficacy for the weight problems capsule on the finish of the day is pushed by dose. Increased doses are required to attain full weight-loss potential for weight problems,” Lange says. The Wegovy capsule is 25 milligrams whereas Rybelsus is 14 milligrams.
The commonest uncomfortable side effects of oral Wegovy embrace nausea and vomiting, that are additionally uncomfortable side effects of the injectable model.
Novo has not disclosed the precise timeline for the drug’s launch, however Lange says it is going to be obtainable someday within the first few months of 2026. Manufacturing of the medicine is already underway at Novo Nordisk’s US manufacturing websites, and the corporate expects to have sufficient of the drug to satisfy US demand.
